News
DGAP-News: Abivax veröffentlicht Finanzergebnisse für das erste Halbjahr 2022 und gibt Update zur Unternehmensentwicklung
DGAP-News: Abivax: Phase-2b-Studienergebnisse mit Obefazimod (ABX464) in Colitis ulcerosa in Fachzeitschrift „The Lancet Gastroenterology & Hepatology” veröffentlicht
DGAP-News: Abivax gibt erfolgreiche, überzeichnete cross-over Finanzierung über insgesamt EUR 49,2 Mio. mit hochkarätigen US-amerikanischen und europäischen Biotech-Investoren bekannt
DGAP-News: Abivax gibt Änderung seiner Führungsstruktur/Governance im Aufsichtsrat bekannt
DGAP-News: Abivax erhält Genehmigung des US Institutional Review Boards für das Phase-3-Studienprogramm mit Obefazimod zur Behandlung von Colitis ulcerosa
BOIRON : Projected timetable of the next publications and events 2023
The projected timetable of the next publications and events for the year 2023 is the following one:
Publications Date of publication (after market closing) Information meetings
The Bastide Group enters the respiratory care devices market in Italy
Caissargues, July 18, 2022
The Bastide Group announces the acquisition of a majority stake in Oxystore, a company based near Milan, Italy. Oxystore specializes in home diagnosis and online sales of
Theranexus publishes its cash position as of 30 june 2022
Lyon, France – 12 July 2022 – 6 pm CEST – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating
Quantum Genomics announces the appointment of its new Scientific Advisory Board
Quantum Genomics announces the appointment of its new Scientific Advisory Board
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development
DGAP-News: Abivax gibt die Ergebnisse seiner am 9. Juni abgehaltenen ordentlichen und außerordentlichen Jahreshauptversammlung bekannt
THERANEXUS PARTICIPATES IN SEVERAL LEADING SCIENTIFIC CONFERENCES AND BUSINESS CONVENTIONS
Lyon, France – 9 June 2022– 6 pm CEST – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the
DGAP-News: Abivax: Phase-2a-Studienergebnisse mit Obefazimod (ABX464) in RA in Fachzeitschrift “Annals of the Rheumatic Diseases” veröffentlicht und für Präsentation auf dem EULAR-Kongress ausgewählt
DGAP-News: Abivax kündigt ordentliche und außerordentliche Jahreshauptversammlung für den 9. Juni 2022 an und stellt Sitzungsunterlagen bereit
BASTIDE : Acceleration in growth in the third quarter, to 6% - Outlook confirmed
Caissargues, May 12, 2022
In €k 2020-2021 2021-2022 Change 3rd quarter revenue 111,669 118,446 +6.1% 9-month revenue 333,033 341,491 +2.5%
Group
Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH
Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH
Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in
Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs
Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs
Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development
QUANTUM GENOMICS : Publication of the Universal Registration Document
Publication of the Universal Registration Document
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal
Quantum Genomics publishes its results for fiscal 2021 and gives an update on its activity
Quantum Genomics publishes its results for fiscal 2021 and gives an update on its activity
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the
DGAP-News: Abivax veröffentlicht Referenzdokument 2022 'Document d'Enregistrement Universel'
QUANTUM GENOMICS : Update of Shareholding Situation Following April 27, 2022 Capital Raise
Update of Shareholding Situation Following April 27, 2022 Capital Raise
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a
Quantum Genomics announces successful capital raising with a gross sum of approximately EUR 15.6 M EUR
Quantum Genomics announces successful capital raising with a gross sum of approximately €15.6 M€
- Quantum Genomics has equipped itself with new financial means to pursue the development of
Quantum Genomics Raises a Gross Amount of Approximately EUR 15 M
Quantum Genomics Raises a Gross Amount of Approximately € 15 M
- Launch of capital increase of approximately €15 million for institutional investors with cancellation of the pre-emptive subscription
Theranexus publishes its 2021 full-year results And announces a shift of its strategic focus to rare neurological diseases
Lyon, France – 25 April 2022 – 7:00 am CEST –Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating
BOIRON : 2022 first quarter sales
(Unaudited data)
In thousands of euros 2022 2021 Variation at current exchange rates Variation at constant exchange rates France 77,055 51,518 +49.6% +49.6% Europe
Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606
Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606
Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the